NUTRITIONAL INTERVENTION FOR CANCER CACHEXIA

Information

  • Research Project
  • 6016542
  • ApplicationId
    6016542
  • Core Project Number
    R43CA083443
  • Full Project Number
    1R43CA083443-01
  • Serial Number
    83443
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/1999 - 26 years ago
  • Project End Date
    7/31/2000 - 25 years ago
  • Program Officer Name
    XIE, HENG
  • Budget Start Date
    8/1/1999 - 26 years ago
  • Budget End Date
    7/31/2000 - 25 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/30/1999 - 26 years ago

NUTRITIONAL INTERVENTION FOR CANCER CACHEXIA

The American Cancer Society estimates that this year alone 564,800 Americans will die of cancer. Scientific evidence also suggests that up to one-third of those deaths are related to malnutrition and cachexia. There are currently no effective nutritional interventions designed to treat the complex syndrome of cancer cachexia. The presence or absence of weight loss is a predictor of survival in patients receiving cancer therapy. Supplemental nutrition is often indicated in severely malnourished patients undergoing surgery, chemotherapy, or radiation therapy. Our goal is to prevent treatment-related morbidity and mortality, deliver optimal anti-neoplastic therapy, alleviate symptoms of cancer cachexia, and improve quality of life. Forty patients with solid tumors who have demonstrated weight loss of 5% or greater in the previous six weeks will be recruited for the study. Patients will be supplemented with either the nutrient combination HMB/arginine/glutamine or a placebo in a double blind fashion. For a period of 24 weeks, body composition will be evaluated by air displacement, plethysmography, bioelectrical impedance analysis, skinfold testing, and circumference measurements. We expect that the HMB/arginine/glutamine combination will result in a positive synergistic action on muscle mass which is anticipated to help cancer patients better tolerate chemotherapeutic regimens and improve longevity and quality of life. PROPOSED COMMERCIAL APPLICATIONS: If this nutritional combination can enhance immune function and lean mass in cancer patients, it will be possible to market this combination in a variety of products. Since over 1.2 million cases of cancer are expected to be diagnosed this year alone (American Cancer Society), there is a large market potential for the proposed nutritional product. The initial product would most likely contain the nutrient combination in a ready-to-drink formulation. A balanced nutritional product containing high quality protein and other nutrients would likely follow. It is envisioned that these products will be highly effective over-the-counter nutritional supplements for cancer patients with diagnosed symptoms of cachexia and result in better treatment outcomes and improved quality of life for the patients.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
  • Organization Name
    METABOLIC TECHNOLOGIES, INC.
  • Organization Department
  • Organization DUNS
    937516276
  • Organization City
    AMES
  • Organization State
    IA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    50010
  • Organization District
    UNITED STATES